Description

Clopixol (Zuclopenthixol) Solution for Injections Ampoules 50 mg. 1ml. №10

Ingredients:

Each ampoule contains 50 mg of zuclopenthixol as the active ingredient. Other ingredients include water for injections, sodium chloride, and hydrochloric acid for pH adjustment.

Dosage:

The usual dose is 50-150 mg every 2-4 weeks, administered by deep intramuscular injection. Dosage may vary based on individual patient response and condition severity.

Indications:

Clopixol injections are indicated for the treatment of schizophrenia and other psychoses. It helps manage symptoms such as hallucinations, delusions, and thought disturbances.

Contraindications:

Do not use Clopixol injections in patients with known hypersensitivity to zuclopenthixol or other components of the formulation. It is contraindicated in comatose or severely depressed patients.

Directions:

Administer Clopixol injections deep into the muscle, rotate injection sites, and follow aseptic techniques. Monitor patients closely for any adverse reactions post-injection.

Scientific Evidence:

Zuclopenthixol, the active ingredient in Clopixol, exerts its antipsychotic effects by blocking dopamine receptors in the brain, particularly the D2 receptors. This action helps alleviate the positive symptoms of schizophrenia, such as hallucinations and delusions.

Clinical trials have demonstrated the efficacy of zuclopenthixol in managing acute psychotic episodes and preventing relapse in patients with schizophrenia. Research published in the Journal of Clinical Psychopharmacology showed that zuclopenthixol injections were effective in reducing symptom severity and improving overall functioning in patients with schizophrenia.

Additional Information:

• Monitoring: Regular monitoring of vital signs, blood parameters, and neurological status is essential during Clopixol therapy.
• Side Effects: Common side effects may include drowsiness, dizziness, and extrapyramidal symptoms. Patients should be informed about these potential adverse reactions.

Overall, Clopixol (zuclopenthixol) solution for injections is a valuable treatment option for individuals suffering from schizophrenia and related psychoses. Its well-established pharmacological action on dopamine receptors, supported by scientific evidence from clinical trials, underscores its efficacy in managing symptoms and improving the quality of life for patients.

Comparative studies have shown that zuclopenthixol exhibits similar effectiveness to other typical antipsychotic medications but with potentially fewer side effects, making it a favorable choice in the treatment algorithm for schizophrenia.